Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.


45th Annual Convention; Chicago, IL; 2019

Event Details

Previous Page


Invited Paper Session #404

Novel Behavioral Targets and Outcomes in Treating Cocaine Use Disorder

Monday, May 27, 2019
8:00 AM–8:50 AM
Swissôtel, Concourse Level, Zurich D
Area: BPN; Domain: Applied Research
Instruction Level: Intermediate
CE Instructor: William Stoops, Ph.D.
Chair: Sally L. Huskinson (University of Mississippi Medical Center)
WILLIAM STOOPS (University of Kentucky)
Dr. William Walton Stoops, a Professor in the Departments of Behavioral Science, Psychiatry and Psychology at the University of Kentucky, earned his Bachelor’s degree in Psychology from Davidson College in Davidson, NC and his Master’s degree and Ph.D. in Psychology from the University of Kentucky. His research evaluates the behavioral and pharmacological factors that contribute to drug use disorders, focusing especially on cocaine use disorder. Dr. Stoops’ research contributions resulted in receipt of the 2016 Psychologist of the Year Award from the Kentucky Psychological Association, the 2013 Joseph Cochin Young Investigator Award from the College on Problems of Drug Dependence and the 2008 Wyeth Young Psychopharmacologist Award from Division 28 (Psychopharmacology and Substance Abuse) of the American Psychological Association (APA). Dr. Stoops currently serves on the ABAI Science Board, chairs the Program Committee for the College on Problems of Drug Dependence and is Editor of Experimental and Clinical Psychopharmacology.

Cocaine use disorder presents an enduring and significant public health concern. Despite decades of research, a widely effective and accepted treatment for cocaine use disorder remains to be identified. The failure to identify treatments may be due, in part, to the only accepted indicator of treatment efficacy: complete abstinence from cocaine. This presentation will provide an overview of human laboratory and clinical trial research that has identified other potential treatment targets that can be adopted as indicators of efficacy. These behavioral targets include attentional bias, inhibitory control and decision making. As the clinical relevance of these novel targets is demonstrated, they may become acceptable treatment outcomes and can be used to identify novel effective interventions for cocaine use disorder.

Target Audience:

Graduate students, Researchers, Board certified behavior analysts, Licensed psychologists

Learning Objectives: At the conclusion of the presentation, participants will be able to: (1) discuss the current state of treatment development for cocaine use disorder; (2) understand how novel treatment targets are evaluated in the human laboratory and in clinical trials; (3) appreciate how novel outcomes can change cocaine treatment development.



Back to Top
Modifed by Eddie Soh